期刊文献+

辅酶Q_(10)在治疗高血压方面的应用进展 被引量:6

Advances in Application of Coenzyme Q_(10) in Treatment of Hypertension
下载PDF
导出
摘要 高血压是心血管疾病最相关的独立危险因素之一,将血压降至正常水平能显著减少心血管事件发生。辅酶Q_(10)是人体自身合成的一种高效内源性脂溶性抗氧化物质,是细胞线粒体氧化呼吸链的固有成分,普通膳食补充并不足以满足病理状态下人体的需要。近年来的大量研究证实,外源性补充辅酶Q_(10)能有效降低高血压患者的收缩压及舒张压,且未发现其引起严重不良事件,其机制可能与减轻氧化应激与改善内皮功能等有关。作为一种安全的补充剂,辅酶Q_(10)在高血压治疗中的应用值得引起重视。 Hypertension is one of the most relevant independent risk factors for cardiovascular disease,and keeping blood pressure at a normal level can reduce cardiovascular events.Coenzyme Q 10 is a highly efficient endogenous fat-soluble antioxidant substance synthesized by the human body.It is an intrinsic component of the mitochondrial oxidative respiratory chain.The ordinary dietary supplement is not enough to meet the needs of the human body under pathological conditions.In recent years,a large number of studies have confirmed that exogenous coenzyme Q 10 can effectively reduce systolic blood pressure and diastolic blood pressure in patients with hypertension,and it has not been found to cause serious adverse events .The mechanism may be related to oxidative stress and endothelial function.As a safe supplement,coenzyme Q 10 is worth of due attention in the treatment of hypertension.
作者 王彬苏 杨宁 杨国红 张芯 李玉明 WANG Binsu;YANG Ning;YANG Guohong;ZHANG Xin;LI Yuming(Logistics University of of the Chinese People's Armed Police Forces,Tianjin 300309,China;Cardiovascular Disease Institute,Affiliated Hospital of Logistic University of of the Chinese People's Armed Police Forces,Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury,Tianjin 300162,China)
出处 《医学综述》 2018年第22期4416-4420,共5页 Medical Recapitulate
基金 天津市科技计划项目(15ZXJZSY00010 16ZXMJSY00130)
关键词 高血压 辅酶Q10 抗高血压药物 子痫前期 Hypertension Coenzyme Q10 Antihypertensive drugs Preeelamipsia
  • 相关文献

参考文献3

二级参考文献37

  • 1张坚,满青青,王春荣,李红,由悦,翟屹,李莹,赵文华.中国18岁及以上人群血脂水平及分布特征[J].中华预防医学杂志,2005,39(5):302-305. 被引量:112
  • 2Peters RM, Flack JM. Hypertensive disorders of pregnancy[J]. J Obstet Gynecol Neonatal Nurs, 2004,33 (2) : 209-220.
  • 3Duley L. The global impact of pre-eclampsia and eclampsia[J]. Semin Perinatol, 2009,33 (3) : 130-137.
  • 4Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclamp- sia and intrauterine growth restriction with aspirin started in early pregnancy[J]. Obstet Gynecol, 2010,116 (2 Pt 1) : 402-414.
  • 5Duley L. Pre-eclampsia, eclampsia, and hypertension[J]. Clin Evid (Online), 2011, pii : 1402.
  • 6Magee LA, Helewa M, Moutquin JM, et al. Diagnosis,evalua- tion, and management of the hypertensive disorders of pregnancy [J]. J Obstet Gynaecol Can,2008,30(3 Suppl) :S1-48.
  • 7American college of obstetricians and gynecologists. ACOG prac- tice bulletin No. 125: chronic hypertension in pregnancy[J]. Obstet Gynecol,2012,119(2 Pt 1) :396-407.
  • 8American college of obstetricians and gynecologists. ACOG prac- tice bulletin No. 29:chronic hypertension in pregnancy[J]. Obstet Gynecol, 2001,98(1) : 177-185.
  • 9ACOG committee on obstetric practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Num- ber 33, January 2002. American college of obstetricians and gynecologists[J]. Int J Gynaecol Obstet, 2002,77 (1) : 67-75.
  • 10Irgens HU, Reisaeter L, Irgens LM, et al. Long term mortality of mothers and fathers after pre-eclampsia: population based co- hort study[J]. BMJ,2001,323(7323) : 1213-1217.

共引文献2240

同被引文献93

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部